Home
Live Updates
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma : comparemela.com
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Related Keywords
Ohio ,
United States ,
James Isaacs ,
Department Of Hematology ,
Medical Oncology ,
Cleveland Clinic ,
Cleveland Clinic Gross Family Melanoma Registry ,
Nivolumab ,
Talazoparib ,
Opdivo ,
Talzenna ,
Nivolumab Plus Talazoparib ,
Melanoma ,
Aacr Annual Meeting ,
Brca ,
comparemela.com © 2020. All Rights Reserved.